A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa

Kodama, Satoru; Abe, Nobuyuki; Hirano, Takashi; Suzuki, Masashi

doi:10.3109/00016489.2011.576429

Cited by 12 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemokine production is important for the induction of mucosal immune responses following vaccination. Although many chemokines are associated with inflammatory responses, recent researches in the biological roles of chemokines such as CCL20 also allow to employ as potential vaccine adjuvants by regulating mucosal immune responses ( 16 , 43 ). Studies have shown that mucosal vaccination increases local chemokine production in the gut mucosa; these chemokines attract immune cells (including IgA-producing plasma cells) to the site of vaccination ( 64 , 65 ).…”

Section: Discussionmentioning

confidence: 99%

“…CCL20, also known as macrophage inflammatory protein-3α, binds to CC chemokine receptor-6 (CCR6) ( 12 ) and attracts immature DCs ( 13 ), memory T cells ( 14 ), and B cells ( 15 ). In addition, increased number of DCs induced by CCL20 upon mucosal vaccination is associated with the extent to which IgA and IgG levels in the nasal mucosa are elevated ( 16 ), indicating that chemokine induction is important for efforts to improve vaccine efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate

et al. 2018

View full text Add to dashboard Cite

Short-chain fatty acids (SCFAs), such as acetate, butyrate, and propionate, modulate immune responses in the gut. However, the effect of SCFAs on mucosal vaccine-induced immune cell migration is poorly understood. Here, we investigated whether SCFAs modulate chemokine expression induced by the killed whole-cell oral cholera vaccine, Shanchol™, in human intestinal epithelial cells. Shanchol™ induced expression of CCL2, CCL5, CCL20, and CXCL10 at the mRNA level, but not at the protein level. Interestingly, CCL20 secretion was substantially increased by co-stimulation with Shanchol™ and butyrate, while neither acetate nor propionate showed such effect. Enhanced CCL20 secretion was associated with GPR109A activation, and histone deacetylase (HDAC) inhibition. In addition, co-treatment with Shanchol™ and butyrate synergistically increased the secretion of adenosine triphosphate (ATP). Moreover, CCL20 secretion was decreased by inhibiting the extracellular ATP receptor P2X7. However, neither inflammasomes nor caspases were involved in CCL20 production. The culture supernatant of cells treated with Shanchol™ and butyrate augmented human immature dendritic cell migration. Collectively, these results suggest that butyrate enhances Shanchol™-induced CCL20 production in human intestinal epithelial cells via HDAC inhibition and ATP-P2X7 signaling by activating GPR109A. These effects potentially enhance the mucosal immune responses in the gut induced by this oral cholera vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate

et al. 2018

View full text Add to dashboard Cite

show abstract

“…76 The addition of CCL20 resulted in significant increases in IgA and IgG titers and a subsequent increase in nasopharyngeal clearance of NTHi. The same group tested the efficacy of fms-like tyrosine kinase receptor 3 ligand as a mucosal adjuvant with P6 protein.…”

Section: Progress In Identification Of New Vaccine Candidatesmentioning

confidence: 99%

Panel 6: Vaccines

Pettigrew

Alderson

Barenkamp

et al. 2017

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources PubMed database of the National Library of Science. Review Methods We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.

show abstract

“…In comparison with MIP-1β and MCP-1, mucosal genetic co-transfer of MIP-2 or MIP-1α with genetic antigen rendered recipients (mice) more resistant to HSV intravaginal infection. Nasal application of MIP-3α with P6 protein of nontypable Haemophilus influenzae (NTHi) induced an increase in the number of dendritic cells in murine NALT and P6-specific nasal wash IgA and serum IgG titers (Kodama et al, 2011 ). Accordingly, the clearance of NTHi was enhanced in MIP-3α immunized group.…”

Section: Mips and Mcpsmentioning

confidence: 99%

Innate endogenous adjuvants prime to desirable immune responses via mucosal routes

Wang

Meng

2014

Protein Cell

View full text Add to dashboard Cite

Vaccination is an effective strategy to prevent infectious or immune related diseases, which has made remarkable contribution in human history. Recently increasing attentions have been paid to mucosal vaccination due to its multiple advantages over conventional ways. Subunit or peptide antigens are more reasonable immunogens for mucosal vaccination than live or attenuated pathogens, however adjuvants are required to augment the immune responses. Many mucosal adjuvants have been developed to prime desirable immune responses to different etiologies. Compared with pathogen derived adjuvants, innate endogenous molecules incorporated into mucosal vaccines demonstrate prominent adjuvanticity and safety. Nowadays, cytokines are broadly used as mucosal adjuvants for participation of signal transduction of immune responses, activation of innate immunity and polarization of adaptive immunity. Desired immune responses are promptly and efficaciously primed on basis of specific interactions between cytokines and corresponding receptors. In addition, some other innate molecules are also identified as potent mucosal adjuvants. This review focuses on innate endogenous mucosal adjuvants, hoping to shed light on the development of mucosal vaccines.

show abstract

A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa

Cited by 12 publications

References 22 publications

Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate

Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate

Panel 6: Vaccines

Innate endogenous adjuvants prime to desirable immune responses via mucosal routes

Contact Info

Product

Resources

About